Anti-S100A8 & S100A9, Recombinant [5.5]
Invented at Cancer Research UK London Research Institute: Lincoln's Inn Fields
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 153260 |
| Applications | ELISA FACS IHC IP WB |
| Antigen/Gene or Protein Targets | S100A8 (MRP-8) & S100A9 (MRP-14) |
| Reactivity | Human |
| Relevance | S100A8 (MRP-8) and S100A9 (MRP-14) are cytosolic calcium-binding proteins of 8kDa and 14kDa that form a heterodimer. S100A8 and S100A9 are expressed in secretory and inflamed keratinocytes, peripheral blood monocytes, neutrophils and has been described in platelets, dendritic cells and some T cell types. Expression is lost on tissue maturation of monocytes to macrophages. S100A9 may be associated with monocyte and neutrophil activation and the accumulation of these cells in inflammatory sites. |
| Host | Mouse |
| Immunogen | Acute monocytic leukaemia cells. |
| Subclass | IgG1 |
| Formulation | PBS |
| Concentration | 1mgml-1 |
| Research Area | Cell Signaling & Signal Transduction, Immunology |
| Notes |
Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. Five products based on this clone: - Anti-S100A8 & S100A9 [5.5], Mouse IgG1, Kappa - Anti-S100A8 & S100A9 [5.5], Rabbit IgG, Kappa - Anti-S100A8 & S100A9 [5.5], Human IgG4-S228P, Kappa - Anti-S100A8 & S100A9 [5.5], Human IgG1, Kappa - Anti-S100A8 & S100A9 [5.5], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors. |
References: 1 entry
Original hybridoma first published in: Hogg et al. 1989. Eur J Immunol. 19(6):1053-61. PMID: 2666142.
Add a reference
References: 1 entry
Original hybridoma first published in: Hogg et al. 1989. Eur J Immunol. 19(6):1053-61. PMID: 2666142.
Add a reference
